Valeant revenue forecast misses estimates as competition heats up

(Reuters) – Valeant Pharmaceuticals’ forecast for 2018 revenue fell below Wall Street estimates, as the company faces intensifying competition for some of its major products.

Source: Reuters

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>